Lannett Company Inc. (fka LCINQ)

[Stockhero1]

12 Drugs awaiting FDA approval + 42 Drugs in Pipeline

Here is a REAL UNDISCOVERED and a very very MASSIVE UNDERVALUED stock for those who looking for a SOLID and PROFITBALE Company with SIGNIFICANT UPSIDE POTENTIAL .Get in this LOW FLOAT SLEEPING GIANT now before the stock gets discovered . GLTA


Lannett (LCI) Summary :

Low Float 13 M // Market cap 102 M // Cash 24.3 M // 39 Products already available on the Market // 42 Products in their HUGE Pipeline // 6 Drugs approved and launched in last 5 months and another 12 Drugs awaiting FDA approval // LCI moves into Profitability last Quarter = A ONCE IN A LIFETIME OPPORTUNITY !!!

I think LCI will go over $10++ before summer 2012 IF the Market doesnt Crash !


Lannett (LCI)

Market Cap: $102.7 M
Cash: $24.3 M
Price: $ 3.62

Book Value: $3.76 per share

Shares Out: 28.3 M ( 15 M shares held by Insider and Institutions)
Low Float: 13 M




14 Drugs awaiting FDA Approval and 42 Drugs in Pipeline
http://cc.talkpoint.com/ubsx001/091911a_im/content/38_MHI46CI/lrgslides/Slide5.png
http://cc.talkpoint.com/ubsx001/091911a_im/content/38_MHI46CI/lrgslides/Slide13.png


CEO bought 20467 shares at $3.90 in September
http://www.benzinga.com/news/11/09/1913233/lannett-company-ceo-purchases-20-467-shares-of-companys-stock


Institutions bought more shares
http://www.dailyfinance.com/quote/amex/lannett-company-inc/lci/ownership
http://www.j3sg.com/Reports/Stock-Insider/xxxgen.php?tickerLookUp=lci&Submit2322=GO&DV=yes#


39 Products already on the Market (Product Catalog)
http://www.lannett.com/docs/Lannett%20-%20Dec%202010%20Catalog%20Final.pdf


Mike Harvilla article from July
http://seekingalpha.com/article/277651-lannett-drops-after-fda-approval-with-more-decisions-pending


from last earnings :

“Our fiscal 2012 first quarter revenues, gross profit and net income all significantly improved over the previous quarter, as well as the prior year first quarter,” said Arthur Bedrosian, president and chief executive officer of Lannett. “Higher sales of Levothyroxine and certain pain management products were the key drivers for the solid performance. Moreover, our bottom line results would have been even better but for the losses on investments recorded during the period.

“We are off to a solid start and continue to expect the six products approved since June 23, 2011, along with our 12 additional product applications pending at the FDA, to generate positive momentum for the balance of fiscal 2012,” Bedrosian added.